Streetbeat News

AMLX

Amylyx Pharmaceuticals, Inc.

Industry

Biotechnology

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Open

3.59

Mkt cap

332M

Volume

409K

High

3.82

P/E Ratio

-0.85

52-wk high

7.27

Low

3.57

Div yield

N/A

52-wk low

1.57

Amylyx Pharmaceuticals has announced the publication of a survival analysis comparing the long-term survival of participants in the CENTAUR study versus a historical clinical trial control group. The results of this study could have significant implications for the company's future drug development and approval processes.

Portfolio Pulse from Bill Haddad

October 10, 2023 | 1:16 pm

Amylyx Pharmaceuticals has provided an update on the Accès Compassionnel for its drug AMX0035 in France. The company did not disclose specific details in the news.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 9:28 pm

During Friday's session, 169 companies set new 52-week lows. Among them, Bristol-Myers Squibb was the largest firm by market cap to set a new 52-week low, while Blue Star Foods was the smallest. PTC Therapeutics' stock fell the most, trading down 31.29% to reach a new 52-week low. Meanwhile, Prelude Therapeutics' stock bounced back the most, rising 0.0% after reaching its new 52-week low.

Portfolio Pulse from Benzinga Insights

September 15, 2023 | 3:52 pm

Amylyx Pharma (NASDAQ:AMLX) has received five bullish analyst ratings in the last quarter, with an average price target of $49.8, indicating a potential upside from the current price of $21.55. The average price target has increased by 2.68% over the past month.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 5:00 pm

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Amylyx Pharma (NASDAQ:AMLX) and maintained a $50 price target.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 4:56 pm

Amylyx Pharma (NASDAQ:AMLX) reported Q2 earnings of $0.31 per share, beating the analyst consensus estimate of $0.10 by 210%. This is a 133.33% increase over losses of $(0.93) per share from the same period last year. The company also reported quarterly sales of $98.20 million, beating the analyst consensus estimate of $92.14 million by 6.58%.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:02 pm

Amylyx Pharma (NASDAQ:AMLX) is set to release its latest quarterly earnings report on August 10, 2023. Analysts estimate an earnings per share (EPS) of $0.10. The company's past performance shows a mix of EPS estimates and actuals, with the stock price generally decreasing. Over the last 52-week period, shares are down 15.19%.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 2:01 pm

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Amylyx Pharma (NASDAQ:AMLX) and maintained a $50 price target.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 10:10 am

Goldman Sachs analyst Corinne Jenkins has upgraded Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) from Neutral to Buy, raising the price target from $45 to $49. Jenkins believes that investor concerns about the ongoing Phase III PHOENIX study are overdone and sees the current stock price as an attractive entry point. She also predicts a more than 60% probability of the PHOENIX trial data demonstrating statistical significance.

Portfolio Pulse from Priya Nigam

July 24, 2023 | 6:01 pm

Over the past three months, four analysts have published bullish opinions on Amylyx Pharma (NASDAQ:AMLX) stock. The average price target given by these analysts is $49.75, which is significantly higher than the current price of $22.55. This average has increased by 2.58% from the previous average price target of $48.50.

Portfolio Pulse from Benzinga Insights

July 24, 2023 | 12:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.